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To elucidate mechanisms by which RUNX1–ETO, the common
acute myeloid leukemia t(8;21) fusion protein, primes hemato-
poietic cells for oncogenic transformation, we previously carried
out Affymetrix gene expression profiling of RUNX1–ETO-
expressing human CD34þ progenitor cells.1 We identified the
MYC target gene, MYCT1, as a gene significantly upregulated at
an early developmental stage that could be integral
to RUNX1–ETO-mediated leukemic phenotype (Figure 1).
To determine whether increased MYCT1 expression recapitu-
lates the RUNX1–ETO phenotype, we performed retroviral
transduction of MYCT1 as a single molecular abnormality into
hematopoietic cell lines and normal human cord blood-derived
CD34þ progenitor cells. In the absence of commercially avail-
able MYCT1 antibody, retroviral expression vectors, containing
full-length MYCT1 coding sequence with (MYCT1-HA) or
without (MYCT1) the addition of a C-terminal HA antigen tag,
were also generated (Supplementary Materials and methods
and Supplementary Figure S1), and transgenic MYCT1 over-
expression was confirmed at the mRNA and protein levels
(Supplementary Figure S2). Functional validation (Supplemen-
tary Figure S3) was provided by replication of the reduced
viability of MYCT1-expressing murine myeloid 32D cells in the
absence of WEHI-3B-conditioned medium reported by Yin et al.2
Increased sensitivity to apoptotic stimuli has been reported
for both RUNX1–ETO-expressing cells and cells in which MYC
signalling is deregulated.3 To determine the contribution of
altered MYCT1 expression to primary myeloid progenitor cell
viability, we performed cell survival assays using key hemato-
poietic cytokines. As shown in Figure 2a, cells transduced
with MYCT1 showed significantly reduced intrinsic viability
in the absence of serum and cytokine supplements: a five-fold
reduction in number of viable MYCT1-expressing monocytes
compared with GFP controls was measured after 48 h in culture.
A lesser two-fold reduction in viable MYCT1-expressing
granulocytes was also measured, suggesting that MYCT1
expression impacts on the survival of both lineages. Taken in
combination with the reduced viability of MYCT1-expressing
mouse 32D cells in the absence of IL-3, these results indicate
that MYCT1 expression negatively impacts on survival or alters
the threshold of trophic signalling required to prevent the
activation of apoptosis in myeloid cells. MYCT1-expressing cells
cultured in the presence of IL-3, SCF, G-CSF, IL-6, TNF-a or TPO
experienced slightly reduced or unchanged viability compared
with GFP control cells that only reached statistical significance
at specific doses in cells of monocyte lineage (Supplementary
Figure S3). In striking contrast, MYCT1-expressing monocytes
demonstrated a notable increase in cell survival responses to
GM-CSF over a wide range of doses (Figure 2b). The mean dose
of GM-CSF required to support 50% maximal cell survival
(defined as the number of live cells measured in the highest dose
culture) was three-fold lower for MYCT1-expressing monocytes
than GFP controls (data not shown). An increase in granulocytic
cell survival was also observed but was not statistically
significant (data not shown). These experiments unveil GM-
CSF as unique amongst all cytokines assayed in its ability to
counteract the substantially-diminished intrinsic viability of
MYCT-expressing cells. MYCT1 may, therefore, be involved in
the translation of anti-apoptotic signals from the GM-CSF
receptor in myeloid cells and amplify the GM-CSF signalling
that supports abnormal granulopoiesis in RUNX1–ETO-expres-
sing cells,4 promoting monocyte lineage in the absence of this
oncoprotein. The different magnitude in responses between
granulocytes and monocytes may reflect the differential activa-
tion of STAT3 and STAT5 downstream signalling components in
these lineages.5
To determine whether MYCT1 expression alters hematopoie-
tic cell proliferative capacity as well as intrinsic viability, we
performed bulk culture of MYCT1-expressing and GFP control
populations, measuring live cell numbers over 30 days.
Interestingly, no differences in viability of MYCT1-expressing
cells were detected under these conditions of cytokine and
serum sufficiency and, instead, a moderate but significant
increase in population growth was observed over time (1.5-fold
compared with GFP control after 21 days; Figure 3a). This
MYCT-driven expansion is in contrast to the absence of growth
reported previously in MYCT1-expressing murine fibroblasts.2
This disparity may reflect the context-dependent differential
activity of MYCT1, highlighting an important role for this
transcription factor in hematopoiesis. However, the former
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report followed cell growth only as far as 5 days, so that late-
onset or more modest influences of MYCT1 may have been
missed. Distinct from RUNX1–ETO-expressing CD34þ cells,6
there was no transient growth inhibition detected for MYCT1-
expressing cells, suggesting that MYCT1 exerts disparate effects
on growth regulatory networks from RUNX1–ETO. The dual
effects of increased growth and propensity to apoptosis
promoted by MYCT1 expression are consistent with a role in
MYC-mediated cellular transformation.
The phenotype of MYCT1-expressing cells in bulk culture was
assessed by multicolour flow cytometry to discern any lineage-
selective proliferative activity to parallel the increased survival
of MYCT1-expressing monocytes observed in survival assays.
We have previously demonstrated retention of CD34 hemato-
poietic progenitor cell marker expression by RUNX1–ETO-
expressing cells, as well as a reduction in maturing granulocytes
characteristic of t(8;21) leukaemia.6 However, we detected no
significant shift in the distributions of monocyte, granulocyte
and erythrocyte populations in bulk cultures of MYCT1-
expressing cells (Figure 3b), and the downregulation of
CD34þ expression between day 6 and 9 of culture was
comparable with control populations and in accordance with
normal programs of lineage maturation. Equivalent proportions
of monocyte and granulocyte populations measured in MYCT1
and GFP control cultures were sustained beyond the time at
which detectable differences in overall growth were detected
(day 21; Figure 3a and data not shown), suggesting that the
expansion of MYCT1-expressing cultures over time is not
lineage-specific. These data indicate that MYCT1 over-expres-
sion does not maintain cells in an undifferentiated state or alter
normal lineage commitment and maturation in these culture
conditions.
To determine any selective promotion of monocyte
self-renewal under more restrictive conditions, we performed
colony-forming assays by limiting dilution. Although the
expression of MYCT1 did not significantly affect the overall
colony-forming efficiency, we found a consistent trend for
increased frequency (1.2-fold) of monocyte colonies compared
with control cells (Supplementary Figure S4A). Interestingly, we
also measured an increase in mean size of MYCT1-expressing
monocyte colonies, which were 1.5-fold bigger than GFP
control monocyte colonies (Supplementary Figure S4B). There
was little discernible effect on size in the other lineages
Figure 1 Up-regulation of MYCT1 expression by RUNX1–ETO in
human CD34þ hematopoietic progenitor cells. Normal human
CD34þ hematopoietic progenitor cells were purified from human
cord blood and infected with RUNX1–ETO or control vector
expressing GFP alone. (a) Total RNA from pair-matched RUNX1–
ETO and GFP control transduced cells was extracted by lysis in Trizol
on day 3 of culture and subjected to Affymetrix microarray analysis
to determine differential MYCT1 gene expression. (b) Quantitative
RT–PCR (qRT–PCR) analysis of MYCT1 expression in GFP control and
RUNX1–ETO transduced cells. Normalised expression values were
determined by crossing point analysis ofMYCT1 signal compared with
ABL housekeeping gene control in duplicate samples. Fold change
was calculated using the 2DDCt method. Data represents mean±1 s.d.
(n43). Statistical significance was calculated by unpaired t-test,
nPo0.05 and paired t-test, wPo0.01.
Figure 2 GM-CSF supports enhanced survival of MYCT1-expressing
monocytes that show reduced intrinsic viability. MYCT1 and GFP
control transduced day 4 hematopoietic progenitor cells were subjected
to survival assays in the absence of serum. (a) Untreated MYCT1-
expressing monocytes and granulocytes show reduced intrinsic viability
compared with GFP control cells. The proportion of viable cells (%) was
calculated as the number of viable monocytes or granulocytes recovered
after 48 h/equivalent input populations at time zero. (b) MYCT1-
expressing monocytes have increased viability in a broad range of
GM-CSF doses compared with GFP control cells. The proportion
of viable cells (%) in each cytokine dose was normalised to the
proportion of viable cells in the absence of cytokine (untreated cells)
after 48 h. Data represents mean plus±1 s.d. (n¼3) and statistical
significance was calculated by paired t-test, nPo0.05 and wPo0.01.
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examined, corroborating our findings of greater impact of
aberrant MYCT1 expression for the monocyte lineage under
conditions of restricted trophic support. These results are distinct
from those we have obtained using RUNX1–ETO-expressing
cells, where a suppression of granulocyte colony formation
without concomitant increase in monocyte colony-forming
capacity was determined.6 However, we did observe a more
than two-fold increase in the numbers of monocyte colonies
forming from RUNX1–ETO-expressing cells plated at later
hematopoietic stages of development (days 9 and 16) compared
with GFP controls. The impact of MYCT1 expression for
monocyte colony frequency and size also parallels the
enhanced self-generative capacity of macrophage progenitor
cells and monocytic tumour development reported in mice
expressing low levels of a MYC transgene.7 Thus, effects on
monocyte/macrophage renewal are seen with RUNX1–ETO and
MYC as well as MYCT1 deregulation.
In summary, these results suggest MYCT1 transcription can
be activated downstream of RUNX1–ETO as well as MYC,
contributing to key aspects of the leukaemic phenotypes these
oncoproteins promote, as well as the specific promotion of
monocyte survival and sensitivity to GM-CSF. We have recently
uncovered an analogous downregulation of the lineage-mod-
ulating transcription factor, GFI1B8 by both RUNX1–ETO and
MYCT1 in human hematopoietic progenitor cells, which is
mirrored in t(8;21) acute myeloid leukemia patients (Supple-
mentary Figure S5 and Supplementary Table 1). This novel gene
network highlights MYCT1 as a key node in aberrant RUNX1–
ETO and MYC signalling and merits further investigation as a
potential mechanism for the myeloid expansion and maturation
block that characterises acute myeloid leukemia disease.
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Figure 3 MYCT1 expression promotes population expansion without
altering lineage distributions in bulk liquid culture. Following retroviral
transduction, MYCT1 and GFP control transgenic CD34þ cells were
cultured in medium supplemented with 5ng/ml IL-3, SCF, G-CSF and
GM-CSF for 30 days at 37 1C. At the time-points indicated, liquid cultures
were analysed by four-colour immunophenotypic analysis. (a) MYCT1-
expressing hematopoietic progenitor cells demonstrate increased growth
over 30 days in culture compared with GFP control cells. (b) MYCT1-
expressing and GFP control cells generate analogous proportions of
erythrocyte (CD13lo CD36hi), monocyte (CD13hi CD36hi) and granulo-
cyte (CD13hi CD36lo) populations on days 6 and 9 of bulk culture. There
is no differential retention of the CD34þ progenitor cell marker. Data
represents mean plus±1 s.d. (n¼ 3) and statistical significance was
calculated by paired t-test, nPo0.05 and wPo0.01.
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